NCT00277732已完成不适用
Pharmaceutical Care for Diabetes Type 2 Patients: a Randomised Controlled Trial
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 288
- 试验地点
- 2
- 主要终点
- The difference between the study groups in the change of blood glucose and HbA1c
研究概览
简要总结
The objective of this study is to evaluate the therapeutic effectiveness and cost-effectivity of pharmaceutical care for diabetes type 2 patients. Patients will be randomly allocated to the control group ( = no input from pharmacist) or intervention group ( = with pharmaceutical care at baseline and follow-up visits over 6 months).
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 45 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •45-75 years
- •Body Mass Index >= 25
- •Diabetes treatment for at least 12 months
- •Regular visitors of the participating community pharmacy
排除标准
- •Patients taking only insulin (no oral antidiabetic drugs)
结局指标
主要结局
The difference between the study groups in the change of blood glucose and HbA1c
时间窗: baseline and after 6 months
次要结局
- Knowledge about diabetes and treatment(after 6 months)
- Therapy adherence
- Body Mass Index(after 6 months)
- Periods of severe hypoglycemia
- GP visits, emergency room visits and hospitalisations
- Work days lost
- Frequency of eye and foot examination
研究者
研究点 (2)
Loading locations...
相似试验
已完成
2 期
A Phase 2 Study to Evaluate Efficacy and Safety of VX-561 in Subjects Aged 18 Years and Older With Cystic FibrosisCystic FibrosisNCT03911713Vertex Pharmaceuticals Incorporated77
已完成
2 期
Efficacy and Safety Study of Efgartigimod in Adults With Post-COVID-19 POTSPostural Orthostatic Tachycardia SyndromeNCT05633407argenx53
进行中（未招募）
1 期
The Combination Regimen of Elbasvir (EBR)/Grazoprevir (GZR) in Pediatric Participants with Chronic Hepatitis C InfectioEUCTR2015-003006-16-SEMerck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.57
进行中（未招募）
1 期
The Combination Regimen of Elbasvir (EBR)/Grazoprevir (GZR) in Pediatric Participants with Chronic Hepatitis C InfectioEUCTR2015-003006-16-DEMerck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.57
进行中（未招募）
1 期
The Combination Regimen of Elbasvir (EBR)/Grazoprevir (GZR) in Pediatric Participants with Chronic Hepatitis C InfectioChronic genotype 1 or genotype 4 Hepatitis C Virus infectionMedDRA version: 20.1Level: LLTClassification code 10047457Term: Viral hepatitis CSystem Organ Class: 100000004862EUCTR2015-003006-16-PLMerck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.57